Latest News

18 October 2022

Journal of Parkinson’s Disease Transitioning to Gold Open Access in 2023

Amsterdam, October 20, 2022 – The Journal of Parkinson’s Disease (JPD), published by IOS Press, is pleased to announce that beginning in January 2023, JPD will transition to a Gold Open Access publication. This means that all articles published after that date will be immediately and permanently freely available online for readers to view, download, share, and reuse, and will enable authors to comply more easily with funder and institutional mandates.

17 June 2022

NWO Stevin Prize for Expert on Parkinson’s Disease Bas Bloem

Bas Bloem

Neurologist Bas Bloem, MD, PhD, FRCPE of Radboud University Medical Center receives this year’s Stevin Prize of the Dutch Research Council (NWO). The Stevin Award is the highest distinction in science for a researcher in the Netherlands who has achieved particular success in the area of knowledge utilization for society. Prof. Bloem is the recipient of this award for the social impact of his research into this common and debilitating disorder.

20 May 2022

Journal of Parkinson’s Disease Welcomes New Co-Editor-in-Chief Lorraine V. Kalia, MD, PhD, FRCPC

Lorraine Kalia

The Journal of Parkinson’s Disease is pleased to announce the appointment of new co-Editor-in-Chief, Lorraine V. Kalia, MD, PhD, FRCPC. Dr. Kalia joins co-Editor-in-Chief Bas Bloem, MD, PhD, FRCPE, and an eminent international editorial board, who are dedicated to the continuing success of the world’s leading journal in Parkinson’s research.

10 May 2022

Involving Patients with Parkinson’s Disease in Research Benefits Everyone

JPD news

Although there is a growing trend to involve patients in clinical research, specific guiding principles for engaging individuals with Parkinson’s disease have not been established. The authors of this Call to Action emphasize the value of incorporating patient perspectives in clinical Parkinson’s disease studies and recommend how to include patient researchers effectively.

14 April 2022

Patrik Brundin Steps Down as JPD Co-Editor-in-Chief

Patrik Brundin

We share the news that Patrik Brundin, MD, PhD has decided to step down as co-Editor-in-Chief (EIC), of the Journal of Parkinson’s Disease, with immediate effect, following his acceptance of a new position at Roche Pharmaceutical Research and Early Development. As a consequence of his moving away from academia, he now steps down from the journal to prevent any form of conflict of interests.

15 March 2022

Skin Biopsy Can Help Identify Patients with Parkinson’s Disease

The diagnosis of Parkinson’s disease (PD) is currently based on consensus clinical criteria. A novel study in JPD has found that the presence of neuronal deposits of the biomarker phosphorylated alpha-synuclein in the brain and the skin of patients with PD distinguishes them from individuals with symptoms of parkinsonism due to the accumulation of another protein, tau.

30 September 2021

Promoting Diversity, Equity, and Inclusion in Parkinson’s Research and Care

Current knowledge about Parkinson’s disease (PD) does not reflect the diversity of people with the disease, according to The Michael J. Fox Foundation for Parkinson’s Research (MJFF). In a position paper published in JPD, MJFF research staff define four major areas of action to reduce health disparities and advance treatments for everyone with PD. It highlights steps the Foundation is taking in these areas, including a new program launched earlier this year.

23 September 2021

Pipeline of Cell and Gene Therapies Holds Promise for Repairing the Parkinsonian Brain

grey scale visual of jigsaw pieces joining to form the head and brain

After several decades of pre-clinical development, cell- and gene-based therapies for Parkinson’s disease (PD) are now actively being explored. In this JPD special issue on “Repairing the Parkinsonian Brain,” experts highlight some of the current strategies being pursued to restore lost function and replace what is lost in the PD brain, with special emphasis on the challenges associated with translating advanced therapeutic approaches into pioneering clinical trials.

Pages

Subscribe to Latest News